Abstract:The COVID-19 pandemic represents a global challenge that has impacted and is expected to continue to impact the lives and health of people across the world for the foreseeable future. The rollout of vaccines has provided highly anticipated relief, but effective therapeutics are required to further reduce the risk and severity of infections. Monoclonal antibodies have been shown to be effective as therapeutics for SARS-CoV-2, but as new variants of concern (VoC) continue to emerge, their utility and use have waned due to limited or no efficacy against these variants. Furthermore, cumbersome systemic administration limits easy and broad access to such drugs. As well, concentrations of systemically administered antibodies in the mucosal epithelium, a primary site of initial infection, are dependent on neonatal Fc receptor mediated transport and require high drug concentrations. To reduce the viral load more effectively in the lung, we developed an inhalable formulation of a SARS-CoV-2 neutralizing antibody binding to a conserved epitope on the Spike protein, ensuring pan-neutralizing properties. Administration of this antibody via a vibrating mesh nebulization device retained antibody integrity and resulted in effective distribution of the antibody in the upper and lower respiratory tract of non-human primates (NHP). In comparison with intravenous administration, significantly higher antibody concentrations can be obtained in the lung, resulting in highly effective reduction in viral load post SARS-CoV-2 challenge. This approach may reduce the barriers of access and uptake of antibody therapeutics in real-world clinical settings and provide a more effective blueprint for targeting existing and potentially emerging respiratory tract viruses. COVID-19, caused by the SARS-CoV-2 virus, has had a global impact since the beginning of 2020. Although vaccines were developed and accepted under emergency procedures in under a year–certain populations still remain vulnerable for the viral infection. Monoclonal antibodies could be very potent against viral infections and respiratory diseases, but SARS-CoV-2 has presented many challenges in that field. One being the speed of emerging mutations, which has prevented many developed antibodies from working against later variants, and the other is the route of administration. Here, we developed two monoclonal antibodies of which one lost its virus neutralizing activity due to the mutations in Spike protein. As the second antibody maintained its effectiveness despite the mutational dynamics, we tested it in a viral challenge with non-human primates. We show that nebulization of therapeutic antibody provides significantly higher antibody concentrations in the lungs and airways, where most of the viral replication takes place. Therefore, nebulization could provide a more accessible and effective way of managing respiratory viruses, minimizing potential side effects and cost.

Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants

A Potent Neutralizing Nanobody Against SARS-CoV-2 with Inhaled Delivery Potential

Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2

Intranasal delivery of a broadly neutralizing single domain antibody targeting ACE2 protects against SARS-CoV-2 infection

Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in Hace2 Mice Conferred by an Intranasal Nanobody (Nb22)

Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants

Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates

Conversion of Monoclonal IgG to Dimeric and Secretory IgA Restores Neutralizing Ability and Prevents Infection of Omicron Lineages

Next-generation intranasal Covid-19 vaccine: a polymersome-based protein subunit formulation that provides robust protection against multiple variants of concern and early reduction in viral load of the upper airway in the golden Syrian hamster model

An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants

Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice

Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters

A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration

Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants

Protecting mucosal innate immunity against SARS-CoV-2 variant of concern

Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain

A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration

Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2

Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron